|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Kuai WX, Wang Q, Yang XZ, Zhao Y, Yu R and
Tang XJ: Interleukin-8 associates with adhesion, migration,
invasion and chemosensitivity of human gastric cancer cells. World
J Gastroenterol. 18:979–985. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bünger S, Haug U, Kelly FM,
Klempt-Giessing K, Cartwright A, Posorski N, Dibbelt L, Fitzgerald
SP, Bruch HP, Roblick UJ, von Eggeling F, Brenner H and Habermann
JK; BMBF-Consortium ‘Colorectal Cancer Screening Chip’. Toward
standardized high-throughput serum diagnostics: multiplex-protein
array identifies IL-8 and VEGF as serum markers for colon cancer. J
Biomol Screen. 16:1018–1026. 2011.
|
|
5
|
Kitadai Y, Takahashi Y, Haruma K, Naka K,
Sumii K, Yokozaki H, Yasui W, Mukaida N, Ohmoto Y and Kajiyama G:
Transfection of interleukin-8 increases angiogenesis and
tumorigenesis of human gastric carcinoma cells in nude mice. Br J
Cancer. 81:647–653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsuo Y, Ochi N, Sawai H, Yasuda A,
Takahashi H, Funahashi H, Takeyama H, Tong Z and Guha S: CXCL8/IL-8
and CXCL12/SDF-1alpha co-operatively promote invasiveness and
angiogenesis in pancreatic cancer. Int J Cancer. 124:853–861. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ju D, Sun D, Xiu L, Meng X, Zhang C and
Wei P: Interleukin-8 is associated with adhesion, migration and
invasion in human gastric cancer SCG-7901 cells. Med Oncol.
29:91–99. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohamed MM: Monocytes conditioned media
stimulate fibronectin expression and spreading of inflammatory
breast cancer cells in three-dimensional culture: a mechanism
mediated by IL-8 signaling pathway. Cell Commun Signal. 10:32012.
View Article : Google Scholar
|
|
9
|
Asfaha S, Dubeykovskiy AN, Tomita H, Yang
X, Stokes S, Shibata W, Friedman RA, Ariyama H, Dubeykovskaya ZA,
Muthupalani S, Ericksen R, Frucht H, Fox JG and Wang TC: Mice that
express human interleukin-8 have increased mobilization of immature
myeloid cells, which exacerbates inflammation and accelerates colon
carcinogenesis. Gastroenterology. 144:155–166. 2013. View Article : Google Scholar
|
|
10
|
Shi HL, Wu XJ, Liu Y and Xie JQ: Berberine
counteracts enhanced IL-8 expression of AGS cells induced by
evodiamine. Life Sci. 93:830–839. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Milovanovic J, Todorovic-Rakovic N and Abu
Rabi Z: The prognostic role of interleukin-8 (IL-8) and matrix
metalloproteinases -2 and -9 in lymph node-negative untreated
breast cancer patients. J BUON. 18:866–873. 2013.PubMed/NCBI
|
|
12
|
Hartman ZC, Poage GM, den Hollander P,
Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck
SG, Mills GB and Brown PH: Growth of triple-negative breast cancer
cells relies upon coordinate autocrine expression of the
proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73:3470–3480.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Singh JK, Farnie G, Bundred NJ, Simões BM,
Shergill A, Landberg G, Howell SJ and Clarke RB: Targeting CXCR1/2
significantly reduces breast cancer stem cell activity and
increases the efficacy of inhibiting HER2 via HER2-dependent and
-independent mechanisms. Clin Cancer Res. 19:643–656. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Todorović-Raković N and Milovanović J:
Interleukin-8 in breast cancer progression. J Interferon Cytokine
Res. 33:563–570. 2013.PubMed/NCBI
|
|
15
|
Freund A, Chauveau C, Brouillet JP, Lucas
A, Lacroix M, Licznar A, Vignon F and Lazennec G: IL-8 expression
and its possible relationship with estrogen-receptor-negative
status of breast cancer cells. Oncogene. 22:256–265. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Freund A, Jolivel V, Durand S, Kersual N,
Chalbos D, Chavey C, Vignon F and Lazennec G: Mechanisms underlying
differential expression of interleukin-8 in breast cancer cells.
Oncogene. 23:6105–6114. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T,
Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL,
Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB,
Johnson MD, Lippman M, Ethier S, Gazdar A and Gray JW: A collection
of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Britschgi A, Andraos R, Brinkhaus H,
Klebba I, Romanet V, Mϋller U, Murakami M, Radimerski T and
Bentires-Alj M: JAK2/STAT5 inhibition circumvents resistance to
PI3K/Mtor blockade: a rationale for cotargeting these pathways in
metastatic breast cancer. Cancer Cell. 22:796–811. 2012. View Article : Google Scholar
|
|
19
|
Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q,
Zhu J, Chen JJ, Huang RC, Chen ZS and Huang RP: Enhanced
chemosensitization in multidrug-resistant human breast cancer cells
by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat.
135:737–747. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Juvekar A and Wulf GM: Closing escape
routes: inhibition of IL-8 signaling enhances the anti-tumor
efficacy of PI3K inhibitors. Breast Cancer Res. 15:3082013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Collins TS, Lee LF and Ting JP: Paclitaxel
up-regulates interleukin-8 synthesis in human lung carcinoma
through an NF-kappaB-and AP-1-dependent mechanism. Cancer Immunol
Immunother. 49:78–84. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Larco JE, Wuertz BR, Manivel JC and
Furcht LT: Progression and enhancement of metastatic potential
after exposure of tumor cells to chemotherapeutic agents. Cancer
Res. 61:2857–2861. 2001.PubMed/NCBI
|
|
23
|
Lev DC, Onn A, Melinkova VO, Miller C,
Stone V, Ruiz M, McGary EC, Ananthaswamy HN, Price JE and Bar-Eli
M: Exposure of melanoma cells to dacarbazine results in enhanced
tumor growth and metastasis in vivo. J Clin Oncol. 22:2092–2100.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kishida O, Miyazaki Y, Murayama Y, Ogasa
M, Miyazaki T, Yamamoto T, Watabe K, Tsutsui S, Kiyahara T,
Shimomura I and Shinomura Y: Gefitinib (Iressa, ZD1839) inhibits
SN38-triggered EGF signals and IL-8 production in gastric cancer
cells. Cancer Chemother Pharmacol. 55:584–594. 2005. View Article : Google Scholar
|
|
25
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang JX, Liu J, Wang J, He C and Li FP:
The extract of huanglian, a medicinal herb, induces cell growth
arrest and apoptosis by upregulation of interferon-beta and
TNF-alpha in human breast cancer cells. Carcinogenesis.
26:1934–1939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kuo HP, Chuang TC, Tsai SC, Tseng HH, Hsu
SC, Chen YC, Kuo CL, Kuo YH, Liu JY and Kao MC: Berberine, an
isoquino-line alkaloid, inhibits the metastatic potential of breast
cancer cells via Akt pathway modulation. J Agric Food Chem.
60:9649–9658. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tan W, Li Y, Chen M and Wang Y: Berberine
hydrochloride: anticancer activity and nanoparticulate delivery
system. Int J Nanomed. 6:1773–1777. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu HM, Peng QX, Liu TS, Yang DJ and Chen
XZ: Effect of retro-Zuojin pill on apoptosis and Bcl-2, Bax gene
expression in SGC-7901 cells. Chin J Exp Trad Med Form (Chin).
14:28–31. 2008.
|
|
30
|
Shi HL, Xie JQ and Wu DZ: Effect of
berberine on cell proliferation and IL-8 expression in AGS cells.
Pharmacol Clin Chin Mater Med (Chin). 28:45–48. 2012.
|
|
31
|
Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang
HI, Wang CJ, Yang SF, Liou YS and Kuo WH: Berberine induces
apoptosis in SW620 human colonic carcinoma cells through generation
of reactive oxygen species and activation of JNK/p38 MAPK and Fas
L. Arch Toxicol. 81:719–728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hur JM, Hyun MS, Lim SY, Lee WY and Kim D:
The combination of berberine and irradiation enhances anti-cancer
effects via activation of p38 MAPK pathway and ROS generation in
human hepatoma cells. J Cell Biochem. 107:955–964. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kuo HP, Chuang TC, Yeh MH, Hsu SC, Way TD,
Chen PY, Wang SS, Chang YH, Kao MC and Liu JY: Growth suppression
of HER2-overexpressing breast cancer cells by berberine via
modulation of the HER2/PI3K/Akt signaling pathway. J Agric Food
Chem. 59:8216–8224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ho YT, Lu CC, Yang JS, Chiang JH, Li TC,
Ip SW, Hsia TC, Liao CL, Lin JG, Wood WG and Chung JG: Berberine
induced apoptosis via promoting the expression of caspase-8, -9 and
-3, apoptosis-inducing factor and endonuclease G in SCC-4 human
tongue squamous carcinoma cancer cells. Anticancer Res.
29:4063–4070. 2009.PubMed/NCBI
|
|
35
|
Eom KS, Kim HJ, So HS, Park R and Kim TY:
Berberine-induced apoptosis in human glioblastoma T98G cells is
mediated by endoplasmic reticulum stress accompanying reactive
oxygen species and mitochondrial dysfunction. Biol Pharm Bull.
33:1644–1649. 2010. View Article : Google Scholar
|
|
36
|
Xu LN, Lu BN, Hu MM, Xu YW, Han X, Qi Y
and Peng JY: Mechanisms involved in the cytotoxic effects of
berberine on human colon cancer HCT-8 cells. Biocell. 36:113–120.
2012.PubMed/NCBI
|
|
37
|
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason
GA, Christensen JG and Kerbel RS: Accelerated metastasis after
short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Paez-Ribes M, Allen E, Hudock J, Takeda T,
Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Britschgi A, Radimerski T and Bentires-Alj
M: Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast
cancer: which combination makes the whole greater than the sum of
its parts? Drug Resist Updat. 16:68–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lai Y, Shen Y, Liu XH, Zhang Y, Zeng Y and
Liu YF: Interleukin-8 induces the endothelial cell migration
through the activation of phosphoinositide 3-kinase-Rac1/RhoA
pathway. Int J Biol Sci. 7:782–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shao N, Chen LH, Ye RY, Lin Y and Wang SM:
The depletion of interleukin-8 causes cell cycle arrest and
increases the efficacy of docetaxel in breast cancer cells. Biochem
Biophys Res Commun. 431:535–541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chelouche-Lev D, Miller CP, Tellez C, Ruiz
M, Bar-Eli M and Price JE: Different signalling pathways regulate
VEGF and IL-8 expression in breast cancer: implications for
therapy. Eur J Cancer. 40:2509–2518. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bezzerri V, Borgatti M, Finotti A,
Tamanini A, Gambari R and Cabrini G: Mapping the transcriptional
machinery of the IL-8 gene in human bronchial epithelial cells. J
Immunol. 187:6069–6081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang Y, Wang W, Wang L, Wang X and Xia J:
Regulatory mechanisms of interleukin-8 production induced by tumour
necrosis factor-α in human hepatocellular carcinoma cells. J Cell
Mol Med. 16:496–506. 2012.
|
|
45
|
Burger M, Hartmann T, Burger JA and
Schraufstatter IU: KSHV-GPCR and CXCR2 transforming capacity and
angiogenic responses are mediated through a JAK2-3-dependent
pathway. Oncogene. 24:2067–2075. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Uehara N, Kanematsu S, Miki H, Yoshizawa K
and Tsubura A: Requirement of p38 MAPK for a cell-death pathway
triggered by vorinostat in MDA-MB-231 human breast cancer cells.
Cancer Lett. 315:112–121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS,
Jung JS and Kim JM: Role of ERK activation in cisplatin-induced
apoptosis in OK renal epithelial cells. J Appl Toxicol. 25:374–382.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jo SK, Cho WY, Sung SA, Kim HK and Won NH:
MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by
decreasing inflammation and apoptosis. Kidney Int. 67:458–466.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jayasooriya RGPT, Moon DO, Park SR, Choi
YH, Asami Y, Kim MO, Jang JH, Kim BY, Ahn JS and Kim GY: Combined
treatment with verrucarin A and tumor necrosis factor-α sensitizes
apoptosis by overexpression of nuclear factor-kappaB-mediated Fas.
Envir Toxicol Pharmacol. 36:303–310. 2013.
|
|
50
|
Parada E, Egea J, Romero A, del Barrio L,
García AG and López MG: Poststress treatment with PNU282987 can
rescue SH-SY5Y cells undergoing apoptosis via α7 nicotinic
receptors linked to a Jak2/Akt/HO-1 signaling pathway. Free Radic
Biol Med. 49:1815–1821. 2010.PubMed/NCBI
|
|
51
|
Chen Q, Lu Z, Jin Y, Wu Y and Pan J:
Triptolide inhibits Jak2 transcription and induces apoptosis in
human myeloproliferative disorder cells bearing Jak2V617F through
caspase-3-mediated cleavage of Mcl-1. Cancer Lett. 291:246–255.
2010. View Article : Google Scholar
|
|
52
|
Will B, Siddiqi T, Jorda MA, Shimamura T,
Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG and Kobayashi
S: Apoptosis induced by JAK2 inhibition is mediated by Bim and
enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid
cells. Blood. 115:2901–2909. 2010. View Article : Google Scholar : PubMed/NCBI
|
